Author's posts
Specialty Generics: Barriers To Uptake
One would expect the specialty generic value proposition for payers and patients – clinical equivalence at a lower cost – to be as positive as the traditional generic value proposition. But, there are several barriers to effective specialty generic pri…
Risk-Sharing Arrangements May Boost Fortunes Of Certain Prescription Drugs
Following establishment of risk-sharing arrangements, sales volume for certain drugs has gradually increased. This is not to say that risk-sharing has been the only driving factor, but it appears to be one of several key factors.
Priority Review Vouchers Revitalizing Neglected Disease Drug Development
There’s room for cautious optimism with respect to neglected tropical disease drug development, as recently the issuance of priority review vouchers in exchange for neglected disease drug approvals has picked up considerably.
The New Anti-Flu Drug Xofluza’s Value Proposition
An improved clinical benefit profile together with the potential for diminished physician service and hospital spending appear to justify the Xofluza’s price premium relative to Tamiflu.
Trump’s Proposed Medicare Drug Pricing Experiment Stokes Fears Of Price Controls
Trump’s proposed Medicare drug pricing experiment raises questions concerning the appropriateness of the method used to calculate the international price index, and the fact that U.S. prices would piggyback on price controls set in non-U.S. jurisdictions.
Edge In U.S. Cancer Drug Development Spurred By Regulatory And Reimbursement Policies
A relatively unbridled market with few reimbursement restrictions and a plethora of proactive regulatory incentives appear to be driving the trend towards more cancer drug approvals in the U.S. versus Europe.
Improving Drug Price Transparency: From Removing Pharmacy Gag Clauses To Reforming The Rebate System
Given the importance of rebates to the current drug pricing system, state and federal changes designed to either establish transparent rebates or discounts, or get rid of rebates altogether, could significantly impact drug pricing and formulary managem…
Measuring Well-Being: It’s More Than GDP
At a time when GDP is rising at a steady clip while simultaneously overall life expectancy is falling, it behooves the federal government to systematically record and report healthcare system successes and failures.
Why It’s Not So Simple To Standardize The Guides Insurers Use To Pay For Off-Label Cancer Drugs
Oncologists have called for an overhaul of drug compendia cited in connection with off-label use reimbursement of cancer drugs. While there is insufficient evidence for some approved off-label uses of cancer drugs, having multiple sources is preferable…
Possible Removal Of Pre-Existing Conditions Protections
A lawsuit by 20 U.S. states seeks to invalidate pre-existing condition protections contained in the Affordable Care Act. Removal of the pre-existing conditions clause may trigger a large number of state legislatures to attempt to enact partial or full …
